What Should an Executive Physical Include in 2026?

The uncomfortable evidence on the traditional executive physical

Start with the finding most executive health programs do not put in their brochure. A Cochrane systematic review of general health checks in adults — 17 trials, more than 250,000 participants — found that routine comprehensive check-ups had little or no effect on all-cause mortality, cardiovascular mortality or cancer mortality, while reliably increasing the number of new diagnoses and treatments.

Fifteen years earlier, writing in the New England Journal of Medicine, Brian Rank made the sharper version of the argument: the executive physical bundles tests that have never demonstrated benefit in asymptomatic adults, allocates scarce medical resources by job title rather than clinical need, and generates incidental findings that trigger downstream procedures with real complication rates.

Both critiques are aimed at the same failure mode — testing breadth substituting for decision quality. A whole-body scan, a resting ECG and a 40-marker panel can produce an impressive report while leaving the questions that actually determine a 55-year-old's next twenty years unanswered: How much plaque is already in the arteries? How insulin-resistant is the metabolism? What is the measured aerobic capacity? Is the airway collapsing 30 times an hour during sleep?

Layer 1 — Resolve cardiovascular risk to particles and plaque

Cardiovascular disease remains the leading cause of death among adults in the executive age band, and it is the domain where standard testing most consistently underperforms. A conventional lipid panel plus a treadmill stress test is the default. Neither answers the central question.

The European Atherosclerosis Society consensus statement, synthesising genetic, epidemiologic and randomised evidence, concluded that LDL causes atherosclerotic cardiovascular disease, and that the causal exposure is cumulative particle-years — not a single snapshot value. Because each atherogenic particle carries exactly one apolipoprotein B molecule, ApoB counts the particles directly. A JAMA Cardiology narrative review found that when ApoB and LDL cholesterol disagree — common in insulin resistance, high triglycerides and normal-weight metabolic dysfunction — ApoB is the better predictor of risk.

Lipoprotein(a) is the second omission. It is largely genetically determined, requires a single lifetime measurement in most adults, is elevated in roughly one in five people, and independently raises risk of myocardial infarction and aortic stenosis. It is almost never on a standard panel, and it changes how aggressively everything else is treated.

Then the anatomy. A coronary artery calcium (CAC) score is a low-dose, non-contrast CT that measures calcified plaque already present. A score of zero in an asymptomatic middle-aged adult identifies a group with markedly low near-term event rates, while a high score reclassifies patients upward regardless of how reassuring their risk calculator output looked. The American College of Cardiology / American Heart Association cholesterol guideline explicitly positions CAC as a decision aid when statin therapy is uncertain — precisely the situation most executives are in.

Blood pressure deserves a specific note because it is the most under-executed intervention in executive medicine. SPRINT randomised more than 9,300 high-risk adults to intensive versus standard systolic targets and was stopped early: intensive control reduced major cardiovascular events and all-cause mortality. The finding is not exotic. It simply requires accurate measurement and follow-through — two things an annual one-off visit is structurally bad at.

Layer 2 — Catch metabolic dysfunction years before it is diabetes

Fasting glucose and HbA1c are lagging indicators. By the time either crosses a diagnostic threshold, insulin resistance has typically been present for years, and beta-cell function has already declined. The American Diabetes Association's Standards of Care define the diagnostic cut-points; they do not claim those cut-points represent the beginning of the disease.

A metabolically useful executive panel therefore looks earlier: fasting insulin alongside glucose, triglyceride-to-HDL ratio, liver enzymes with imaging where indicated for hepatic steatosis, and waist circumference rather than BMI alone. In practice, these markers move first and respond fastest to intervention — which makes them the most motivating numbers in the entire report.

Layer 3 — Measure fitness and body composition, do not estimate them

If a single number had to represent long-term mortality risk, cardiorespiratory fitness would be a defensible choice. In a cohort of more than 122,000 patients who underwent treadmill testing, Mandsager and colleagues found no observed upper limit of benefit: mortality fell with each increment of fitness, and the adjusted risk associated with the lowest fitness quintile exceeded that associated with coronary artery disease, diabetes or smoking.

The American Heart Association's scientific statement went further, arguing cardiorespiratory fitness should be treated as a clinical vital sign and measured routinely. Very few executive physicals actually measure it. Estimating fitness from a questionnaire — or from a stress test read only for ischaemia — discards the most prognostic variable in the room.

• VO2 max or a validated submaximal estimate, retested to show direction of travel
• Grip strength — in the PURE study of nearly 140,000 adults across 17 countries, each 5 kg reduction was associated with higher all-cause and cardiovascular mortality
• DEXA or equivalent for lean mass, fat mass and visceral adipose tissue, which BMI cannot distinguish
• Objective daily step count, where meta-analysis shows mortality declining with higher counts and plateauing around 6,000–8,000 steps in older adults

Layer 4 — Cancer screening, on guideline rather than on impulse

This is where premium programs most often drift from evidence toward theatre. The disciplined position is to execute the guideline-recommended screens completely and on time — and to be candid about the status of everything beyond them.

The US Preventive Services Task Force lowered the colorectal cancer screening start age to 45 for average-risk adults, and expanded annual low-dose CT lung cancer screening to adults 50–80 with a 20 pack-year history who currently smoke or quit within 15 years — the latter grounded in the National Lung Screening Trial, which showed a 20% reduction in lung cancer mortality relative to chest radiography. Skin, breast, cervical and prostate screening follow their own guideline logic and shared decision-making.

Whole-body MRI and multi-cancer early detection blood tests occupy a different category. They are increasingly marketed as the centrepiece of elite physicals, but neither has yet demonstrated a mortality benefit in asymptomatic adults, and both generate incidental findings at meaningful rates. The American College of Radiology's incidental findings work has documented how routinely those findings cascade into further imaging, biopsy and anxiety. A program can reasonably offer them; it should not present them as established preventive medicine.

The question is never whether a test can find something. It is whether finding it changes the outcome.

Layer 5 — Sleep, cognition and load: the executive-specific layer

Sleep-disordered breathing is the most commonly missed diagnosis in this population. Wisconsin Sleep Cohort analyses estimated moderate-to-severe sleep-disordered breathing in a substantial minority of middle-aged adults, with prevalence rising alongside obesity — and the majority remain undiagnosed. Untreated, it drives hypertension, arrhythmia, insulin resistance and daytime cognitive impairment: the exact profile a high-performing executive attributes to travel and workload.

A serious program screens for it with a validated instrument and home sleep testing where indicated, and screens formally for depression, anxiety, alcohol use and burnout. These are not soft additions. They are among the few findings in an executive physical with immediate, high-magnitude consequences for both the individual and the organisation.

The part almost no program gets right: what happens on day two

Every element above is available somewhere. The variable that separates programs is not the panel — it is execution. A finding of ApoB 120 mg/dL, CAC of 180, fasting insulin of 18 µIU/mL and VO2 max in the 30th percentile is, in most executive physicals, a paragraph in a report. It should be the start of a physician-directed treatment plan, a coaching cadence that survives a travel schedule, and a defined re-measurement date.

Cochrane's null result on health checks is, read carefully, largely a null result on measurement without a delivery system. The tests were performed. The behaviour, prescribing and follow-up around them were not reorganised. That gap is the actual product of a modern executive health program.

How to evaluate a program before you buy one

1. 01Does the panel include ApoB and a one-time Lp(a), or does it stop at standard cholesterol?
2. 02Is coronary artery calcium scoring available and interpreted by a physician for appropriate candidates?
3. 03Is cardiorespiratory fitness measured and retested — not estimated from a questionnaire?
4. 04Are early metabolic markers included, or only fasting glucose and HbA1c?
5. 05Are guideline cancer screens actually completed and tracked, rather than merely recommended?
6. 06Is sleep-disordered breathing screened for with a validated tool?
7. 07Who owns the plan after the report — a named physician and a named strategist, with scheduled re-measurement, or nobody?
8. 08Are non-evidence-based add-ons presented honestly as exploratory rather than as standard of care?

A program that answers the first six well and the seventh convincingly is doing modern executive health. One that leads with the length of its panel and the luxury of its facility is selling the 1980s version at 2026 prices.